지연성운동장애(TD) 치료제 시장 : 치료 유형별, 약제별, 유통별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2023-2030년)

REPORT HIGHLIGHT

Tardive Dyskinesia Therapeutics Market size was valued at USD 2,340 Million in 2022, expanding at a CAGR of 9.1% from 2023 to 2030.

Tardive Dyskinesia (TD) treatments are medical procedures that try to relieve the uncontrollable and irregular movements that might occur as a consequence of long-term usage of certain antipsychotic medicines. These therapy techniques include pharmaceutical therapies such as antipsychotic adjustments or VMAT2 inhibitors, which aid in the management of TD symptoms. Non-pharmacological treatments such as behavioral counseling and deep brain stimulation can additionally be used. The purpose of TD therapies is to reduce or eliminate the disruptive motor manifestations of TD, therefore enhancing patients' general level of life and giving respite from the sometimes-upsetting symptoms of this medication-induced mobility disorder.

Tardive Dyskinesia Therapeutics Market- Market Dynamics

Increasing recognition of the condition's impact on patients' well-being to propel market demand

As public and medical professional understanding grows, there is a greater emphasis on early detection and treatment of TD symptoms. This encourages pharmaceutical companies to conduct novel therapeutic research and development, which includes VMAT2 inhibitors, to address unmet medical needs. Furthermore, regulatory authorities' support for expediting TD drug approval stresses the need to offer individuals safe and effective choices. The collaborative efforts to develop TD treatment options are driven by a desire to enhance patient's quality of life and reduce the effect of this movement disorder.

Tardive Dyskinesia Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global Tardive Dyskinesia Therapeutics market is estimated to grow annually at a CAGR of around 9.1% over the forecast period (2023-2030)

The Tardive Dyskinesia Therapeutics industry is projected to grow at a significant rate due to increasing recognition of the condition's impact on patients' well-being

Based on Treatment Type segmentation, Pharmacological Therapies was predicted to show maximum market share in the year 2022

Based on Drug segmentation, Deutetrabenazine was the leading type in 2022

On the basis of region, North America was the leading revenue generator in 2022

Tardive Dyskinesia Therapeutics Market- Segmentation Analysis:

The Global Tardive Dyskinesia Therapeutics Market is segmented on the basis of Treatment Type, Drug, Distribution, and Region.

The market is divided into two categories based on Treatment Type: Pharmacological Therapies, Non-pharmacological Therapies. The Pharmacological Therapies dominates the market. Pharmacological medications are in high demand in the treatment of Tardive Dyskinesia (TD). To control TD symptoms, patients seek effective drugs such as VMAT2 inhibitors and antipsychotic modifications. The pharmaceutical industry is focused on creating safe and tailored medicines to meet the rising need for better pharmacological choices in TD therapy.

The market is divided into three categories based on Drug: Deutetrabenazine, Valbenazine, Others. The Deutetrabenazine sector dominates the market and is likely to maintain its dominance during the forecast period. Deutetrabenazine, a VMAT2 inhibitor, is becoming more popular in the treatment of Tardive Dyskinesia (TD). Its capacity to modulate dopamine levels provides promise for efficiently treating TD symptoms. The demand for deutetrabenazine highlights its potential as a beneficial treatment option in TD management as patients and healthcare professionals seek novel solutions.

Tardive Dyskinesia Therapeutics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. A variety of variables influence the market for Tardive Dyskinesia (TD) medicines in North America. The area has a large population on antipsychotic drugs, which raises the risk of TD. The growing awareness of the effects of TD among healthcare professionals and patients necessitates the development of appropriate therapies. Regulatory approval expedites the availability of novel medicines. The well-established pharmaceutical industry and extensive healthcare system assist TD medicinal research, development, and dissemination. The increased frequency of mental illnesses requiring antipsychotic treatment emphasises the need of addressing TD, making North America a critical market for novel medications targeted at controlling and reducing TD symptoms.

Tardive Dyskinesia Therapeutics Market- Competitive Landscape:

Key pharmaceutical participants in the Tardive Dyskinesia (TD) treatment landscape include Neurocrine Biosciences, Teva, and Bausch Health. These firms are at the forefront of VMAT2 inhibitors and antipsychotic modifications. Treatment effectiveness, safety profiles, and market penetration are all important factors in market competitiveness. The rivalry is shaped by clinical studies, governmental approvals, and marketing initiatives. Niche players concentrate on novel non-pharmacological techniques. Collaborations and collaborations foster innovative therapy research and development. The competitive climate is dynamic, with a rising patient population and increased awareness seeking to meet unmet requirements of TD patients and deliver effective solutions for controlling this complex movement condition.

Recent Developments:

In May 2023, During Tardive Dyskinesia Awareness Week Neurocrine Biosciences, Inc. highlighted its continuing support for raising awareness about the prevalence, impact, and relevance of screening for tardive dyskinesia (TD). TD is an involuntary movement condition caused by long-term use of certain mental health medications (antipsychotics) intended to treat depression, schizophrenia, bipolar disorder,and schizoaffective disorder.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET KEY PLAYERS

• Neurocrine Biosciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• Sunovion Pharmaceuticals Inc.
• Teikoku Pharma USA, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Neurolixis, Inc.
• Retrophin, Inc.
• NeuroSearch A/S
• Abide Therapeutics, Inc.
• Cynapsus Therapeutics Inc.
• Ichor Medical Systems
• Reviva Pharmaceuticals Inc.
• Acorda Therapeutics, Inc.
• Adamas Pharmaceuticals, Inc.

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY TREATMENT TYPE

• Pharmacological Therapies
• Non-pharmacological Therapies

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY DRUG

• Deutetrabenazine
• Valbenazine
• Others

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY DISTRIBUTION

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY REGION

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Tardive Dyskinesia Therapeutics Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Tardive Dyskinesia Therapeutics Market Snippet by Treatment Type
  • 2.1.2. Tardive Dyskinesia Therapeutics Market Snippet by Drug
  • 2.1.3. Tardive Dyskinesia Therapeutics Market Snippet by Distribution
  • 2.1.4. Tardive Dyskinesia Therapeutics Market Snippet by Country
  • 2.1.5. Tardive Dyskinesia Therapeutics Market Snippet by Region
• 2.2. Competitive Insights

3. Tardive Dyskinesia Therapeutics Key Market Trends

• 3.1. Tardive Dyskinesia Therapeutics Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Tardive Dyskinesia Therapeutics Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Tardive Dyskinesia Therapeutics Market Opportunities
• 3.4. Tardive Dyskinesia Therapeutics Market Future Trends

4. Tardive Dyskinesia Therapeutics Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Tardive Dyskinesia Therapeutics Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Tardive Dyskinesia Therapeutics Market Landscape

• 6.1. Tardive Dyskinesia Therapeutics Market Share Analysis, 2022
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Tardive Dyskinesia Therapeutics Market - By Treatment Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Treatment Type, 2022 & 2030 (%)
  • 7.1.2. Pharmacological Therapies
  • 7.1.3. Non-pharmacological Therapies

8. Tardive Dyskinesia Therapeutics Market - By Drug

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Drug, 2022 & 2030 (%)
  • 8.1.2. Deutetrabenazine
  • 8.1.3. Valbenazine
  • 8.1.4. Others

9. Tardive Dyskinesia Therapeutics Market - By Distribution

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Distribution, 2022 & 2030 (%)
  • 9.1.2. Hospital Pharmacies
  • 9.1.3. Drug Stores & Retail Pharmacies
  • 9.1.4. Online Pharmacies

10. Tardive Dyskinesia Therapeutics Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Tardive Dyskinesia Therapeutics Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Tardive Dyskinesia Therapeutics Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. Neurocrine Biosciences, Inc.
  • 11.2.2. Teva Pharmaceutical Industries Ltd.
  • 11.2.3. Bausch Health Companies Inc.
  • 11.2.4. Sunovion Pharmaceuticals Inc.
  • 11.2.5. Teikoku Pharma USA, Inc.
  • 11.2.6. Otsuka Pharmaceutical Co., Ltd.
  • 11.2.7. Neurolixis, Inc.
  • 11.2.8. Retrophin, Inc.
  • 11.2.9. NeuroSearch A/S
  • 11.2.10. Abide Therapeutics, Inc.
  • 11.2.11. Cynapsus Therapeutics Inc.
  • 11.2.12. Ichor Medical Systems
  • 11.2.13. Reviva Pharmaceuticals Inc.
  • 11.2.14. Acorda Therapeutics, Inc.
  • 11.2.15. Adamas Pharmaceuticals, Inc.

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us